Investment Thesis
Atai Beckley N.V. exhibits severe financial distress with a pre-revenue or near-zero revenue business model generating massive operating losses of -74.1M on just 3.0M in revenue. The company is burning cash rapidly with -55.2M in operating cash flow and -56.0M in free cash flow, depleting its limited cash reserves despite maintaining a strong balance sheet from recent capital raises.
ATAI Strengths
- Strong liquidity position with 7.90x current ratio and 30.4M cash on hand
- Zero long-term debt providing financial flexibility
- Equity cushion of 159.8M limiting immediate solvency risk
ATAI Risks
- Massive operating losses of -74.1M with negative operating margin of -2450.5% indicating unsustainable business model
- Severe cash burn rate of -56.0M annually will deplete cash reserves in approximately 6 months at current rate
- Revenue of 3.0M is minimal and declining YoY, suggesting product commercialization failure or pre-revenue status
- Net losses of -115.2M with negative ROE of -72.1% and ROA of -48.1% indicate fundamental value destruction
- No clear path to profitability with operating expenses far exceeding revenue generation capacity
Key Metrics to Watch
- Quarterly revenue growth trajectory and new product launches
- Operating cash burn rate and remaining cash runway
- Operating expense reduction progress and path to profitability
- Progress on clinical trials or regulatory approvals if pharmaceutical development company
- Working capital management and cash depletion timeline
ATAI Financial Metrics
ATAI Profitability Ratios
ATAI Balance Sheet & Liquidity
ATAI 5-Year Financial Trend
5-Year Trend Summary: Atai Beckley N.V.'s revenue has declined by 98% over the 5-year period, indicating business contraction. The most recent EPS of $-0.25 indicates the company is currently unprofitable.
ATAI Growth Metrics (YoY)
ATAI Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $40.0K | -$26.3M | $-0.16 |
| Q2 2025 | $273.0K | -$27.7M | $-0.14 |
| Q1 2025 | N/A | -$26.4M | $-0.15 |
| Q3 2024 | $40.0K | -$21.9M | $-0.14 |
| Q2 2024 | $172.0K | -$33.0M | $-0.21 |
| Q1 2024 | N/A | -$26.7M | $-0.17 |
| Q3 2023 | $24.0K | -$21.9M | $-0.14 |
| Q2 2023 | $170.0K | -$33.0M | $-0.21 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
ATAI Capital Allocation
ATAI SEC Filings
Access official SEC EDGAR filings for Atai Beckley N.V. (CIK: 0001840904)